Showing results (1-10 of 587) with videos related to

Sort By:
Pageof 59
Cancer Research and Treatment|September 8, 2018
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, et al.
Cancer Research and Treatment|September 25, 2020
A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, et al.
Thoracic Cancer|March 14, 2019
Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancerJoon-Young Yoon, Cheol-Kyu Park, Yoo-Duk Choi, et al.
Thoracic Cancer|August 15, 2015
Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinomaHayoung Choi, Jinsun Chang, Hong-Joon Shin, et al.
Thoracic Cancer|December 17, 2019
Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancerSeongho Park, Yoo-Duk Choi, Jieun Kim, et al.
Thoracic Cancer|August 23, 2019
Myasthenia gravis and myopathy after nivolumab treatment for non-small cell lung carcinoma: A case reportJe-Seong Kim, Tai-Seung Nam, Jieun Kim, et al.
Psychiatry Investigation|July 30, 2019
Collaborative Care to Relieve Psychological Distress in Patients with Medically Inoperable Lung Cancer: Design and Rationale for a Clinical TrialSeon-Young Kim, Sung-Wan Kim, Il-Seon Shin, et al.
Tuberculosis and Respiratory Diseases|May 15, 2024
Immune Checkpoint Inhibitor Score Predicts Survival Benefit of Immunotherapy in Patients with Non-small Cell Lung CancerDa Hyun Kang, Chang-Min Choi, Cheol-Kyu Park, et al.
Thoracic Cancer|April 3, 2021
Efficacy and dose of afatinib in patients with non-small cell lung cancer after failure of prior gefitinib or erlotinib treatmentHayoung Choi, Jae-Kyeong Lee, Hyung-Joo Oh, et al.
Oncology|March 5, 2018
A Prospective Observational Study Evaluating the Correlation of c-MET Expression and EGFR Gene Mutation with Response to Erlotinib as Second-Line Treatment for Patients with Advanced/Metastatic Non-Small-Cell Lung CancerCheol-Kyu Park, In-Jae Oh, Yoo-Duk Choi, et al.
Pageof 59